(Total Views: 344)
Posted On: 05/24/2020 7:33:16 AM
Post# of 36551
GNBT is not a vaccine company. Antigen Express, EvH, and soon NGIO have had vaccines as a major part of their portfolio for nearly two decades. COVID stopped, or at least slowed the R&D world. If a company had anything that could serve as anti-viral, it would almost be immoral not to pursue it.
However, Generex has many other irons in the fire. We are waiting patient for funding through the S-1; then we will wait to see how that money is spent; then we look forward to uplisting to the NAZ; then we look for progress in creation of the MSO; hopefully, funds remain to resurrect the diabetes franchise.
Success in producing an effective COVID vaccine would enhance the company greatly. Lack of immediate success will not close Generex down.
However, Generex has many other irons in the fire. We are waiting patient for funding through the S-1; then we will wait to see how that money is spent; then we look forward to uplisting to the NAZ; then we look for progress in creation of the MSO; hopefully, funds remain to resurrect the diabetes franchise.
Success in producing an effective COVID vaccine would enhance the company greatly. Lack of immediate success will not close Generex down.


Scroll down for more posts ▼